Evidence map›Paper›PMID 34288386›Full record

Observational studyPediatric blood & cancer2021

SARS-CoV-2 in children with cancer in Brazil: Results of a multicenter national registry.

Mariana Cristina M Corso, Victor J Soares, Anna Maria P Amorim, Rosana Cipolotti, Isis Maria Q Magalhães, Mecneide M Lins, Silvana Forsait, Luciana N Silva, Ana Virginia L de Sousa, Nádia G Alves and 12 more

Open access · bronzeAbstract readMulticenter StudyObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in Pediatric blood & cancer, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 5 pooled it
2.1field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 5 syntheses or guidelines pooled it, 25 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Review
  7. One-year follow-up of children hospitalized with COVID-19: a prospective cohort study.Jornal brasileiro de pneumologia : publicacao oficial da Sociedade Brasileira de Pneumologia e Tisilogia · 2023
    Article
  8. Article
  9. Article
  10. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors at 15 institutions in 1 country.

Mariana Cristina M CorsoDepartamento de Pediatria, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil.ORCID https://orcid.org/0000-0002-2178-820X
Victor J SoaresFaculdade de Medicina, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil.ORCID https://orcid.org/0000-0003-4022-5952
Anna Maria P AmorimHospital Oncológico Infantil Octávio Lobo, Belém, Brazil.
Rosana CipolottiUniversidade Federal de Sergipe, São Cristóvão, Brazil.ORCID https://orcid.org/0000-0001-9070-2302
Isis Maria Q MagalhãesHospital da Criança de Brasília José Alencar, Brasília, Brazil.
Mecneide M LinsInstituto de Medicina Integral Professor Fernando Figueira, Recife, Brazil.ORCID https://orcid.org/0000-0002-9155-5030
Silvana ForsaitInstituto de Tratamento do Câncer Infantil - ITACI, São Paulo, Brazil.
Luciana N SilvaHospital Martagão Gesteira, Salvador, Brazil.
Ana Virginia L de SousaUniversidade Federal de São Paulo/Instituto de Oncologia Pediátrica - GRAACC, São Paulo, Brazil.
Nádia G AlvesHospital Infantil Albert Sabin, Fortaleza, Brazil.
Seila I do PradoHospital de Câncer de Barretos - Fundação Pio XII, Barretos, Brazil.
Klerize Anecely S SilvaHospital Criança Conceição, Porto Alegre, Brazil.
Edna K CarboneHospital Pequeno Príncipe, Curitiba, Brazil.
Melina BrumattiHospital Israelita Albert Einstein, São Paulo, Brazil.
Pablo SantiagoAssociação Hospitalar Beneficente São Vicente de Paulo, Passo Fundo, Brazil.
Kaline Maria M O PereiraInstituto de Medicina Integral Professor Fernando Figueira, Recife, Brazil.
Fabianne A M C CarlesseUniversidade Federal de São Paulo/Instituto de Oncologia Pediátrica - GRAACC, São Paulo, Brazil.
Marina G AguiarHospital Infantil Albert Sabin, Fortaleza, Brazil.
Rebeca F MarquesLaboratório de Pediatria Translacional, Serviço de Pesquisa Experimental, Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil.
Ciliana RechenmacherDepartamento de Pediatria, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil.ORCID https://orcid.org/0000-0002-1321-5807
Liane E DaudtDepartamento de Pediatria, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil.ORCID https://orcid.org/0000-0001-9495-6932
Mariana B MichalowskiDepartamento de Pediatria, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil.ORCID https://orcid.org/0000-0002-9482-0776
Universidade Federal do Rio Grande do Sul · BRHospital Infantil Albert Sabin · BRInstituto de Medicina Integral Professor Fernando Figueira · BRSupport group for adolescents and children with cancer · BRHospital de Câncer de Barretos · BRHospital de Clínicas de Porto Alegre · BRHospital Erasto Gaertner · BRHospital Geral de Bonsucesso · BRHospital Israelita Albert Einstein · BRHospital Nossa Senhora da Conceição · BRHospital São Rafael · BRHospital São Vicente · BRHospital Universitário de Brasília · BRInstituto de Terapia Integrada e Oriental · BRUniversidade Federal de Sergipe · BR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundStrategies to mitigate the impact of COVID-19 in special populations are complex and challenging. Few studies have addressed the impact of COVID-19 on pediatric patients with cancer in low- and middle-income countries.

methodsMulticenter observational cohort study with prospective records and retrospective analyses starting in April 2020 in 21 pediatric oncology centers distributed throughout Brazil.

participantsPatients under 18 years of age who are infected by the SARS-CoV-2 virus (confirmed diagnosis through reverse transcriptase-polymerase chain reaction [RT-PCR]) while under treatment at pediatric oncology centers. The variables of interest included clinical symptoms, diagnostic and therapeutic measures. The repercussions of SARS-CoV-2 infection on cancer treatment and general prognosis were monitored.

resultsOne hundred seventy-nine patients were included (median age 6 [4-13] years, 58% male). Of these, 55.9% had acute leukemia and 34.1% had solid tumors. The presence of SARS-CoV-2 was diagnosed by RT-PCR. Various laboratory markers were analyzed, but showed no correlation with outcome. Children with low or high BMI for age had lower overall survival (71.4% and 82.6%, respectively) than those with age-appropriate BMI (92.7%) (p = .007). The severity of presentation at diagnosis was significantly associated with outcome (p < .001). Overall mortality in the presence of infection was 12.3% (n = 22).

conclusionIn children with cancer and COVID-19, lower BMI was associated with worse prognosis. The mortality in this group of patients (12.3%) was significantly higher than that described in the pediatric population overall (∼1%).

Indexed as

AdolescentBody Mass IndexBrazilChildChild, PreschoolCOVID-19FemaleHumansMaleNeoplasmsRegistriesRetrospective StudiesRisk FactorsSARS-CoV-2Survival AnalysisBMIcancerCOVID-19pediatric oncologySARS-CoV-2

Identifiers

PMID34288386
PMCPMC8441618
OpenAlexW3185876022

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.